Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis

George Rodrigues, Cary Oberije, Suresh Senan, Kayoko Tsujino, Terry Wiersma, Marta Moreno-Jimenez, Tae Hyun Kim, Lawrence B. Marks, Ramesh Rengan, Luigi De Petris, Sara Ramella, Kim DeRuyck, Nuria Rodriguez De Dios, Andrew Warner, Jeffrey D. Bradley, David A. Palma

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)133-139
JournalInternational Journal of Radiation Oncology Biology Physics
Volume91
Issue number1
DOIs
Publication statusPublished - 1 Jan 2015

Cite this

Rodrigues, G., Oberije, C., Senan, S., Tsujino, K., Wiersma, T., Moreno-Jimenez, M., Kim, T. H., Marks, L. B., Rengan, R., De Petris, L., Ramella, S., DeRuyck, K., Rodriguez De Dios, N., Warner, A., Bradley, J. D., & Palma, D. A. (2015). Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis. International Journal of Radiation Oncology Biology Physics, 91(1), 133-139. https://doi.org/10.1016/j.ijrobp.2014.09.033